147 related articles for article (PubMed ID: 23630208)
1. Treatment of orbital metastases from a primary midgut neuroendocrine tumor with peptide-receptor radiolabeled therapy using 177 lutetium-DOTATATE.
Dobson R; Vinjamuri S; Hsuan J; Banks M; Terlizzo M; Wieshmann H; Daousi C; Poston GP; Cuthbertson DJ
J Clin Oncol; 2013 Jun; 31(17):e272-5. PubMed ID: 23630208
[No Abstract] [Full Text] [Related]
2. Orbital Metastases of Neuroendocrine Tumors Treated With 177Lu-DOTATATE PRRT or 131I-MIBG Therapies.
Makis W; McCann K; McEwan AJ
Clin Nucl Med; 2016 Feb; 41(2):137-41. PubMed ID: 26447382
[TBL] [Abstract][Full Text] [Related]
3. The next generation of peptide receptor radionuclide therapy.
Brabander T; Nonnekens J; Hofland J
Endocr Relat Cancer; 2019 Aug; 26(8):C7-C11. PubMed ID: 31200364
[TBL] [Abstract][Full Text] [Related]
4. 177Lu-Dotatate for midgut neuroendocrine tumours.
Burki TK
Lancet Oncol; 2017 Feb; 18(2):e74. PubMed ID: 28111117
[No Abstract] [Full Text] [Related]
5. Three-dimensional Monte Carlo-based voxel-wise tumor dosimetry in patients with neuroendocrine tumors who underwent
Goetz TI; Lang EW; Prante O; Maier A; Cordes M; Kuwert T; Ritt P; Schmidkonz C
Ann Nucl Med; 2020 Apr; 34(4):244-253. PubMed ID: 32114682
[TBL] [Abstract][Full Text] [Related]
6. Intra-arterial versus standard intravenous administration of lutetium-177-DOTA-octreotate in patients with NET liver metastases: study protocol for a multicenter, randomized controlled trial (LUTIA trial).
Ebbers SC; Braat AJAT; Moelker A; Stokkel MPM; Lam MGEH; Barentsz MW
Trials; 2020 Feb; 21(1):141. PubMed ID: 32024533
[TBL] [Abstract][Full Text] [Related]
7. Symptomatic and Radiological Response to 177Lu-DOTATATE for the Treatment of Functioning Pancreatic Neuroendocrine Tumors.
Zandee WT; Brabander T; Blažević A; Kam BLR; Teunissen JJM; Feelders RA; Hofland J; de Herder WW
J Clin Endocrinol Metab; 2019 Apr; 104(4):1336-1344. PubMed ID: 30566620
[TBL] [Abstract][Full Text] [Related]
8. Bilateral Orbital Soft-Tissue Metastases from Renal Neuroendocrine Tumor: Successful Theranostic Application of
Parghane RV; Basu S
J Nucl Med Technol; 2019 Jun; 47(2):171-172. PubMed ID: 30139884
[TBL] [Abstract][Full Text] [Related]
9. [Radioisotope therapy with somatostatin analogues in neuroendocrine tumours (case report)].
Kunikowska J; Królicki L; Cwikła J; Mikołajczak R; Pawlak D; Korsak A; Kozłowicz I; Poprawski J; Płazińska M; Kobylecka M; Maczewska J; Zycińska K; Wardyn K
Endokrynol Pol; 2005; 56(1):46-54. PubMed ID: 16335674
[TBL] [Abstract][Full Text] [Related]
10. Radionuclide Therapy for Neuroendocrine Tumors.
Cives M; Strosberg J
Curr Oncol Rep; 2017 Feb; 19(2):9. PubMed ID: 28220446
[TBL] [Abstract][Full Text] [Related]
11. ¹⁷⁷Lu-Labeled Agents for Neuroendocrine Tumor Therapy and Bone Pain Palliation in Uruguay.
Balter H; Victoria T; Mariella T; Javier G; Rodolfo F; Andrea P; Graciela R; Juan H; Eugenia de M; Patricia O
Curr Radiopharm; 2016; 9(1):85-93. PubMed ID: 25771367
[TBL] [Abstract][Full Text] [Related]
12. Cardiac metastases of neuroendocrine tumors treated with 177Lu DOTATATE peptide receptor radionuclide therapy or 131I-MIBG therapy.
Makis W; McCann K; Bryanton M; McEwan AJ
Clin Nucl Med; 2015 Dec; 40(12):962-4. PubMed ID: 26359563
[TBL] [Abstract][Full Text] [Related]
13. [Peptide receptor radionuclide therapy of neuroendocrine tumors].
Arveschoug AK; Hjorthaug K; Rehling M; Højgaard L; Mortensen J; Oturai PS
Ugeskr Laeger; 2009 Mar; 171(13):1073. PubMed ID: 19321068
[No Abstract] [Full Text] [Related]
14. NAMPT Inhibitor GMX1778 Enhances the Efficacy of 177Lu-DOTATATE Treatment of Neuroendocrine Tumors.
Elf AK; Bernhardt P; Hofving T; Arvidsson Y; Forssell-Aronsson E; Wängberg B; Nilsson O; Johanson V
J Nucl Med; 2017 Feb; 58(2):288-292. PubMed ID: 27688470
[TBL] [Abstract][Full Text] [Related]
15. A Case Series of Choroidal and Orbital Neuroendocrine Tumors: Metastasis: Two Patients Treated With Peptide Radionuclide Therapy.
Zhuang TZ; Bergstrom C; El-Rayes BF; Shaib WL
Pancreas; 2024 May; 53(5):e445-e449. PubMed ID: 38530952
[TBL] [Abstract][Full Text] [Related]
16. Optimized Peptide Amount and Activity for ⁹⁰Y-Labeled DOTATATE Therapy.
Kletting P; Kull T; Maaß C; Malik N; Luster M; Beer AJ; Glatting G
J Nucl Med; 2016 Apr; 57(4):503-8. PubMed ID: 26678617
[TBL] [Abstract][Full Text] [Related]
17. Cardiac Toxicity in a Patient Receiving Peptide Receptor Radionuclide Therapy.
Hendifar AE; Delpassand ES; Kittleson MM; Tuli R
Pancreas; 2018 Sep; 47(8):e55-e56. PubMed ID: 30113434
[No Abstract] [Full Text] [Related]
18. Liver and bone metastases from small bowel neuroendocrine tumor respond to 177Lu-DOTATATE induction and maintenance therapies.
Makis W; McCann K; Buteau FA; McEwan AJ
Clin Nucl Med; 2015 Feb; 40(2):162-5. PubMed ID: 25243941
[TBL] [Abstract][Full Text] [Related]
19. Cohort study of somatostatin-based radiopeptide therapy with [(90)Y-DOTA]-TOC versus [(90)Y-DOTA]-TOC plus [(177)Lu-DOTA]-TOC in neuroendocrine cancers.
Villard L; Romer A; Marincek N; Brunner P; Koller MT; Schindler C; Ng QK; Mäcke HR; Müller-Brand J; Rochlitz C; Briel M; Walter MA
J Clin Oncol; 2012 Apr; 30(10):1100-6. PubMed ID: 22393097
[TBL] [Abstract][Full Text] [Related]
20. High clinical and morphologic response using
Kong G; Callahan J; Hofman MS; Pattison DA; Akhurst T; Michael M; Eu P; Hicks RJ
Eur J Nucl Med Mol Imaging; 2017 Mar; 44(3):476-489. PubMed ID: 27678267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
